28 February 2026
Pure Global: Brazil's AI MedTech Brief—Decoding ANVISA's Sudden SaMD Rule Shift.
LATAM MedTech Insights
About
This week, we dive into a critical regulatory update from Brazil's ANVISA that is reshaping the landscape for digital health and Software as a Medical Device (SaMD). The new guidance introduces stringent requirements for AI technologies, cybersecurity, and local data management, catching many international MedTech companies off guard.
We explore why existing FDA or CE Mark documentation is no longer enough for the Brazilian market. This episode breaks down the new rules and discusses how adapting to them can provide a significant competitive advantage in Latin America's largest and most lucrative MedTech market.
**Case Study:** A U.S. startup with a cutting-edge AI diagnostic tool was poised to launch in Brazil. Despite having their clinical data and technical file ready, their submission was abruptly halted. The reason? It lacked a detailed cybersecurity vulnerability report adapted to Brazil's specific data privacy laws (LGPD). This unexpected roadblock could delay their launch by over a year, creating an opening for local competitors to seize market share. Are you prepared for this new reality?
**Key Questions Answered:**
* What specific cybersecurity standards has ANVISA now mandated for all SaMD products?
* How does the new guidance re-classify your AI-powered medical software?
* Are your existing clinical validation studies sufficient for the new Brazilian requirements?
* What are the three most common documentation pitfalls for foreign firms under the new guidelines?
* Why is appointing a local Brazil Registration Holder now more critical than ever?
* How can you turn Brazil's tough new regulations into a strategic advantage?
At Pure Global, we specialize in demystifying complex regulatory landscapes. Our local experts in Brazil, combined with our AI-driven data tools, provide end-to-end support for your MedTech and IVD products. We transform regulatory hurdles into market opportunities.
Ready to accelerate your entry into Brazil? Contact us at info@pureglobal.com or visit https://pureglobal.com/.
We explore why existing FDA or CE Mark documentation is no longer enough for the Brazilian market. This episode breaks down the new rules and discusses how adapting to them can provide a significant competitive advantage in Latin America's largest and most lucrative MedTech market.
**Case Study:** A U.S. startup with a cutting-edge AI diagnostic tool was poised to launch in Brazil. Despite having their clinical data and technical file ready, their submission was abruptly halted. The reason? It lacked a detailed cybersecurity vulnerability report adapted to Brazil's specific data privacy laws (LGPD). This unexpected roadblock could delay their launch by over a year, creating an opening for local competitors to seize market share. Are you prepared for this new reality?
**Key Questions Answered:**
* What specific cybersecurity standards has ANVISA now mandated for all SaMD products?
* How does the new guidance re-classify your AI-powered medical software?
* Are your existing clinical validation studies sufficient for the new Brazilian requirements?
* What are the three most common documentation pitfalls for foreign firms under the new guidelines?
* Why is appointing a local Brazil Registration Holder now more critical than ever?
* How can you turn Brazil's tough new regulations into a strategic advantage?
At Pure Global, we specialize in demystifying complex regulatory landscapes. Our local experts in Brazil, combined with our AI-driven data tools, provide end-to-end support for your MedTech and IVD products. We transform regulatory hurdles into market opportunities.
Ready to accelerate your entry into Brazil? Contact us at info@pureglobal.com or visit https://pureglobal.com/.